KETOBA in relation to Ketosis and RECOVERY with BDM30™ at the Arnold Summit

In relation to the novel anti-inflammatory mechanism; executed and discovered at Biologic Pharmamedical Research.

Original post: December 2, 2017

At the recent Arnold Summit, Biologic Pharmamedical delivered a seminar showcasing cutting-edge research led by Dr. Franco Cavaleri on two of our most significant discoveries: KETOBA™ and BDMC™ (Bisdemethoxycurcumin).

The presentation highlighted:

• KETOBA™ Pharmacology (25 minutes) – Exploring its novel role in activating the Nrf2 pathway, improving insulin resistance, and enhancing the physiological state of ketosis. These findings point to exciting therapeutic opportunities in metabolic health and performance optimization.

• BDM™ Pharmacology (20 minutes) – Detailing the unique anti-inflammatory mechanisms of Bisdemethoxycurcumin, including its influence on MyoD activity and its potential in modulating inflammatory pathways linked to chronic disease.

This seminar not only emphasized Biologic’s commitment to advancing nutraceutical pharmacology but also demonstrated how our patented technologies are unlocking first-to-market therapeutic applications with profound implications for human health.

For more information on Biologic Pharmamedical’s research and patented innovations, visit www.biologicpharmamedical.com.

#KETOBA #Ketosis #Recovery #BDM30 #ArnoldSummit #AntiInflammatoryMechanism #BiologicPharmamedical #NRf2Activation #InsulinResistance #CurcuminDiscovery #MyoD #Pharmacology #FrancoCavaleri #InnovativeResearch #HealthSeminar #DietarySupplements #NutritionScience #BiomedicalDiscoveries #AntiInflammatoryActivity #BiomedicalInnovations